替雷利珠单抗联合白蛋白紫杉醇与卡铂治疗Ⅲb~Ⅳ期非小细胞肺癌的临床效果  

Clinical Effect of Tislelizumab Combined with Albumin Paclitaxel and Carboplatin in the Treatment of StageⅢb-ⅣNon-small Cell Lung Cancer

作　　者：张静 杨美林 ZHANG Jing;YANG Meilin(Sir Run Run Hospital Nanjing Medical University,Nanjing 210000,China;不详)

机构地区：[1]南京医科大学附属逸夫医院,江苏南京210000

出　　处：《中外医学研究》2025年第7期45-48,共4页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的:分析替雷利珠单抗联合白蛋白紫杉醇与卡铂治疗Ⅲb~Ⅳ期非小细胞肺癌(NSCLC)的临床效果。方法:选取2020年1月—2024年3月南京医科大学附属逸夫医院收治的102例Ⅲb~Ⅳ期NSCLC患者作为研究对象,根据随机数表法将其分为对照组和观察组,各51例。对照组给予白蛋白紫杉醇联合卡铂治疗,观察组在对照组基础上联合替雷利珠单抗治疗。比较两组近期疗效、血清肿瘤标志物水平及不良反应发生情况。结果:观察组客观缓解率(ORR)、临床控制率(DCR)高于对照组,差异有统计学意义(P<0.05);治疗后,两组癌胚抗原(CEA)、糖类抗原125(CA125)、细胞角蛋白19片段(CYFRA21-1)和鳞状上皮细胞癌抗原(SCC)水平低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组治疗期间不良反应发生率比较,差异无统计学意义(P>0.05)。结论:替雷利珠单抗联合白蛋白紫杉醇与卡铂化疗治疗Ⅲb~Ⅳ期NSCLC患者能提高近期临床效果,降低血清肿瘤标志物水平,且未增加药物不良反应。Objective:To analyze the clinical effect of Tislelizumab combined with Albumin Paclitaxel and Carboplatin in the treatment of stageⅢb-Ⅳnon-small cell lung cancer(NSCLC).Method:A total of 102 patients with stageⅢb-ⅣNSCLC who admitted to Sir Run Run Hospital Nanjing Medical University from January 2020 to March 2024 were selected as the study objects,and they were divided into the control group and the observation group according to random number table method,with 51 cases in each group.The control group was given Albumin Paclitaxel combined with Carboplatin,the observation group was given Tislelizumab on the basis of the control group.The short-term efficacy,serum tumor marker levels and adverse reactions were compared between two groups.Result:The objective remission rate(ORR)and clinical control rate(DCR)in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05);after treatment,the levels of carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),cytokeratin 19 fragment(CYFRA21-1)and squamous cell carcinoma antigen(SCC)in two groups were lower than those before treatment,and those in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05);there was no significant differences in the incidence of adverse reactions between two groups during treatment(P>0.05).Conclusion:Tislelizumab combined with Albumin Paclitaxel and Carboplatin in the treatment of stageⅢb-ⅣNSCLC patients can improve the short-term clinical effect,reduce the level of serum tumor markers,and does not increase adverse drug reactions.

关 键 词：替雷利珠单抗 白蛋白紫杉醇 卡铂 晚期非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]